[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8905 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 8905

To amend the Federal Food, Drug, and Cosmetic Act to reduce the threat 
 of counterfeit drugs to the pharmaceutical supply chain, and to make 
    the pharmaceutical supply chain more robust, while ensuring the 
  authenticity, content, purity, and manufacturing location and batch 
  number of drugs (including COVID-19 therapeutics and vaccines) and 
 allowing patient verification of authenticity, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            December 8, 2020

 Mr. Van Drew introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To amend the Federal Food, Drug, and Cosmetic Act to reduce the threat 
 of counterfeit drugs to the pharmaceutical supply chain, and to make 
    the pharmaceutical supply chain more robust, while ensuring the 
  authenticity, content, purity, and manufacturing location and batch 
  number of drugs (including COVID-19 therapeutics and vaccines) and 
 allowing patient verification of authenticity, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Supply Chain Security and 
Pharmaceutical Authentication Act of 2020''.

SEC. 2. PACKAGES SUBJECT TO PHARMACEUTICAL DISTRIBUTION SUPPLY CHAIN 
              REQUIREMENTS.

    Subparagraph (B) of section 581(11) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360eee(11)) is amended to read as follows:
                    ``(B) Individual saleable unit.--For purposes of 
                this paragraph, an `individual saleable unit' is the 
                smallest solid oral dosage form of product, or other 
                individual solid oral dosage form of product, 
                introduced into commerce by the manufacturer or 
                repackager.''.
                                 <all>